Stanley Cohan
Providence Multiple Sclerosis Center, Providence Brain and Spine Institute
Title: The pitfalls of natalizumab discontinuation in patients with multiple sclerosis and their abatement by minimizing washout duration: The results of four clinical studies
Biography
Biography: Stanley Cohan
Abstract
The pitfalls of natalizumab discontinuation in patients with multiple sclerosis and their abatement by minimizing washout duration:
The results of four clinical studies Multiple sclerosis is a leading cause of serious disability of young and middle-aged people in western nations. Natalizumab, a high efficacy medication for control of multiple sclerosis disease activity, increases risk of progressive multifocal leukoencephalopathy in patients harboring JC virus and may necessitate discontinuing natalizumab. Because discontinuing natalizumab may increase the risk of multiple sclerosis reactivation by 30% or more, strategies to transition patients off natalizumab are needed. These reported studies purposes was to demonstrate that multiple sclerosis reactivation was related to duration of post-natalizumab drug-free washout interval, and by reducing washout duration, risk of multiple sclerosis reactivation could be significantly reduced. These studies employed different methodologies and medications: a retrospective analysis of multiple sclerosis patients treated with dimethyl fumarate after discontinuing natalizumab, 2 prospective studies utilizing washouts of 6, 8, 12 and 16 weeks since last natalizumab before initiating fingolimod therapy, and lastly, 4 weeks since last natalizumab dose prior to initiation of teriflunomide. Results: There was 51% (p=0.0216) relapse risk reduction when starting dimethyl fumarate 90 days or less after the last natalizumab dose compared to waiting more than 90 days. Patients starting fingolimod 8-12 weeks post-natalizumab had a lower risk of clinical disease activity than after 16 weeks washout, and compared to a washout of 6 weeks or less, patients with a washout of more than 8 weeks had an odds ratio of 6.8 (95% CI 1.4, 32.8) for return of disease activity. Utilizing 4-week natalizumab washout, 94% patients remained relapse-free after one year of teriflunomide treatment (95% CI 0.83, 0.98). These studies, utilizing different medications and designs, each demonstrated that minimizing post natalizumab washout was associated with reduced multiple sclerosis reactivation and conform with anticipated results when considering the pharmacodynamics of natalizumab receptor desaturation, and efficacy onset time of these 3 different therapeutic agents.
Recent Publications
1. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled tral of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910
2. Bloomgren G, Richman S, Hotermans C, et al. Risk of antalizumab-associated progressive mutifocal leukoencephalopathy. N Engl J Med 2012; 366:1870-1880
3. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68:395-399
4. Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to dimethyl fumarate: A multicenter retrospective observational study. Mult Scler Relat Disord 2018; 22:27-34